Argenx
ARGX
#530
Rank
HK$352.57 B
Marketcap
HK$5,697
Share price
-1.98%
Change (1 day)
26.32%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): HK$7.50 Billion

According to Argenx 's latest financial reports the company's current earnings are HK$3.60 Billion. In 2024 the company made an earning of HK$0.66 Billion, an increase over its 2023 earnings that were of -HK$2.39 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) HK$7.50 B1025.55%
2024 HK$0.66 B-127.97%
2023 -HK$2.39 Billion-58.25%
2022 -HK$5.71 Billion80.17%
2021 -HK$3.17 Billion
2019 -HK$1.56 Billion124.86%
2018 -HK$0.7 Billion131.81%
2017 -HK$0.3 Billion
2015 -HK$0.15 Billion
2013 -HK$87.18 Million